Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,249 public trials 217 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Active, Not Recruiting

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT06601504

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • Guangxi Medical University Cancer Hospital Nanning, Guangxi, China
  • Wuhan Union Hospital of China Wuhan, Hebei, China
View all 16 locations
View Trial Details
Active, Not Recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +15 more
Locations
  • Lucile Packard Children's Hospital /ID# 240854 Palo Alto, California, United States
  • Nicklaus Children's Hospital /ID# 241174 Miami, Florida, United States
  • New York Medical College /ID# 239208 Valhalla, New York, United States
  • Levine Children's Hospital /ID# 242765 Charlotte, North Carolina, United States
View all 41 locations
View Trial Details
Active, Not Recruiting

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841

Conditions
Follicular Lymphoma Grade 3B, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations
  • Sun Yat-sen University Cancer Hospital Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China
  • Hunan Cancer Hospital Changsha, Hunan, China
View all 13 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810

Conditions
Classic Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Disease Attributes, +14 more
Locations
  • Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630 Mobile, Alabama, United States
  • University of Arkansas for Medical Sciences /ID# 244562 Little Rock, Arkansas, United States
  • Highlands Oncology Group, PA /ID# 245002 Springdale, Arkansas, United States
  • Beverly Hills Cancer Center /ID# 255327 Beverly Hills, California, United States
View all 72 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • University of Arizona Cancer Center - North Campus /ID# 227463 Tucson, Arizona, United States
  • Yuma Regional Medical Center /ID# 261527 Yuma, Arizona, United States
  • University of Arkansas for Medical Sciences /ID# 225703 Little Rock, Arkansas, United States
  • CBCC Global Research, Inc. /ID# 262037 Bakersfield, California, United States
View all 331 locations
View Trial Details

Related conditions